156 related articles for article (PubMed ID: 8968532)
1. Pharmacokinetics and haematological parameters of recombinant human erythropoietin after subcutaneous administrations in horses.
Souillard A; Audran M; Bressolle F; Jaussaud P; Gareau R
Biopharm Drug Dispos; 1996 Dec; 17(9):805-15. PubMed ID: 8968532
[TBL] [Abstract][Full Text] [Related]
2. Kinetics and haematological effects of erythropoietin in horses.
Jaussaud P; Audran M; Gareau RL; Souillard A; Chavanet I
Vet Res; 1994; 25(6):568-73. PubMed ID: 7889038
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of recombinant human erythropoietin in rabbits and 3/4 nephrectomized rats.
Yoon WH; Park SJ; Kim IC; Lee MG
Res Commun Mol Pathol Pharmacol; 1997 May; 96(2):227-40. PubMed ID: 9226757
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients.
Brockmöller J; Köchling J; Weber W; Looby M; Roots I; Neumayer HH
Br J Clin Pharmacol; 1992 Dec; 34(6):499-508. PubMed ID: 1493082
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of lyophilized recombinant human erythropoietin-alpha following single-dose subcutaneous administration in premature newborns.
Melo AM; Costa MT; Porta V; Vaz FA
J Matern Fetal Neonatal Med; 2005 Jan; 17(1):55-8. PubMed ID: 15804788
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
7. Red blood cell erythropoietin, not plasma erythropoietin, concentrations correlate with changes in hematological indices in horses receiving a single dose of recombinant human erythropoietin by subcutaneous injection.
Singh AK; Gupta S; Barnes A; Carlson JM; Ayers JK
J Vet Pharmacol Ther; 2007 Apr; 30(2):175-8. PubMed ID: 17348906
[No Abstract] [Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in rats.
Kato M; Okano K; Sakamoto Y; Miura K; Uchimura T; Saito K
Arzneimittelforschung; 2001 Jan; 51(1):91-5. PubMed ID: 11215332
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in athletes. Blood sampling and doping control.
Souillard A; Audran M; Bressolle F; Gareau R; Duvallet A; Chanal JL
Br J Clin Pharmacol; 1996 Sep; 42(3):355-64. PubMed ID: 8877027
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacology of recombinant human erythropoietin (r-HuEPO).
Flaharty KK
Pharmacotherapy; 1990; 10(2 ( Pt 2)):9S-14S. PubMed ID: 2345710
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats.
Woo S; Krzyzanski W; Jusko WJ
J Pharmacol Exp Ther; 2006 Dec; 319(3):1297-306. PubMed ID: 16973883
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects.
Cheung WK; Goon BL; Guilfoyle MC; Wacholtz MC
Clin Pharmacol Ther; 1998 Oct; 64(4):412-23. PubMed ID: 9797798
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers.
Ramakrishnan R; Cheung WK; Wacholtz MC; Minton N; Jusko WJ
J Clin Pharmacol; 2004 Sep; 44(9):991-1002. PubMed ID: 15317827
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous dose administration in cynomolgus monkeys.
Ramakrishnan R; Cheung WK; Farrell F; Joffee L; Jusko WJ
J Pharmacol Exp Ther; 2003 Jul; 306(1):324-31. PubMed ID: 12676891
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic-pharmacodynamic modelling of recombinant human erythropoietin in athletes.
Varlet-Marie E; Gaudard A; Audran M; Gomeni R; Bressolle F
Int J Sports Med; 2003 May; 24(4):252-7. PubMed ID: 12784166
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and distribution of recombinant erythropoietin in rats.
Kinoshita H; Ohishi N; Kato M; Tokura S; Okazaki A
Arzneimittelforschung; 1992 Feb; 42(2):174-8. PubMed ID: 1610430
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects.
Olsson-Gisleskog P; Jacqmin P; Perez-Ruixo JJ
Clin Pharmacokinet; 2007; 46(2):159-73. PubMed ID: 17253886
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of several subcutaneous doses of erythropoietin: potential implications for blood transfusion.
Sans T; Joven J; Vilella E; Masdeu G; Farrè M
Clin Exp Pharmacol Physiol; 2000 Mar; 27(3):179-84. PubMed ID: 10744344
[TBL] [Abstract][Full Text] [Related]
19. Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin.
Jolling K; Perez Ruixo JJ; Hemeryck A; Vermeulen A; Greway T
Eur J Pharm Sci; 2005 Apr; 24(5):465-75. PubMed ID: 15784336
[TBL] [Abstract][Full Text] [Related]
20. Ketanserin lowers erythropoietin concentration in hemodialyzed patients treated with the hormone.
Borawski J; Mazerska M; Pawlak K; Mysliwiec M
J Cardiovasc Pharmacol; 1995 Oct; 26(4):621-6. PubMed ID: 8569225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
